BPC-157: Mechanism of Action

Mecanismo de Acao

VEGFR2 Activation (Primary Target)

BPC-157 liga-se a and ativa vascular endothelial fator de crescimento receptor 2 (VEGFR2) on celulas endoteliais. Diferentemente de standard ligands, BPC-157 promove VEGFR2 internalizacao — um(a) critico(a) step in activating downstream repair pathways.[7][10]

Src Family Kinase Activation

A 2025 study proposes que BPC-157 adopts a polyproline II helix structure que engages the SH3 domains of Src family kinases (c-Src, Yes, Fyn), relieving autoinibicao and acting como um(a) intracellular "switch" for signal transduction.[11]

VEGFR2-Akt-eNOS Cascade

Upon VEGFR2 binding, BPC-157 desencadeia fosforilacao of Akt (Protein Kinase B), que ativa endothelial nitric oxide synthase (eNOS), producing nitric oxide (NO) — essencial para angiogenese and vascular repair.[7]

Src-Caveolin-1-eNOS Pathway

BPC-157 promove fosforilacao of Src and Caveolin-1 (Cav-1). Under normal conditions, Cav-1 inibe eNOS — BPC-157 disrupts this inhibitory complex, enhancing NO production.[10]

FAK-Paxillin Pathway

In tendon fibroblastos, BPC-157 ativa focal adhesion kinase (FAK) and paxillin, essencial para migracao celular, adhesion, and cytoskeletal organization during reparo tecidual.[12]

JAK-2 / Growth Hormone Receptor Upregulacao

BPC-157 ativa JAK-2, linked to upregulacao of hormonio do crescimento receptors (GHR) on tendon fibroblastos, enhancing tissue sensitivity to hormonio do crescimento.[12][13]

Egr-1/NAB2 Feedback Loop

ERK1/2 ativacao upregula Egr-1 and simultaneamente its corepressor NAB2, establishing a feedback loop que previne uncontrolled angiogenic signaling.[14]

Nitric Oxide System Modulation (Bidirectional)

BPC-157 exibe um(a) unico(a) modulatory interaction com o(a) NO system — it counteracts ambos(as) L-NAME (NOS inhibitor → hipertensao) and L-arginine (NOS substrate → hipotensao), acting como um(a) homeostatic buffer rather do que a strict agonist or antagonist.[15]

Dopamine/Serotonin System Regulation

BPC-157 antagonizes o efeitos of dopamine receptor blockers (haloperidol) and agonists (amphetamine), assim como serotonin syndrome precursors — suggesting a regulatory influence on these neurotransmitter systems rather do que direto(a) ligacao ao receptor.[16]